에서 실시간으로 운영 중이에요! 자세히 알아보기

Inotiv

NOTV

시가총액 US$279만

상장 폐지됨

NOTV은(는) 2026년 6월 10일에 상장 폐지됐어요.

순위로 돌아가기

소개: Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

직원 수: 2,046

건강관리 진단 및 리서치

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 0%

중립 0%

부정적 0%

Inotiv Reaches Agreement to Strengthen Capital Structure and Position Company for Future Growth

WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it has entered into a Restructuring Support Agreement (“RSA”) with its Prepetition First Lien Lenders and Ad Hoc Group of Noteholders, constituting substantially all of its junior creditors, to implemen.

Inotiv Reaches Agreement to Strengthen Capital Structure and Position Company for Future Growth

Inotiv Provides Notice Regarding Cybersecurity Incident

WEST LAFAYETTE, Ind., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, is providing public notice regarding its cybersecurity incident that it became aware of on August 8, 2025.

Inotiv Provides Notice Regarding Cybersecurity Incident

Inotiv, Inc. (NOTV) Q1 2026 Earnings Call Transcript

Inotiv, Inc. (NOTV) Q1 2026 Earnings Call Transcript

Inotiv, Inc. (NOTV) Q1 2026 Earnings Call Transcript

Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update

WEST LAFAYETTE, Ind., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q1 FY 2026”) ended December 31, 2025.

Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update

Inotiv, Inc. to Report Fiscal 2026 First Quarter Financial Results and Host Conference Call on Monday, February 9, 2026

WEST LAFAYETTE, Ind., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2026 first quarter ended December 31, 2025, on Monday, February 9, 2026, before the stock market opens. The Company will host a conference call that same day at 8:30 a.m. Eastern Time to discuss the results.

Inotiv, Inc. to Report Fiscal 2026 First Quarter Financial Results and Host Conference Call on Monday, February 9, 2026

Inotiv Leverages LifeNet Health Proprietary Platform to Advance New Approach Methodologies in Translational Drug Discovery

WEST LAFAYETTE, Ind., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced a strategic initiative to leverage LifeNet Health's proprietary TruVivo® within its Discovery and Translational Sciences business.

Inotiv Leverages LifeNet Health Proprietary Platform to Advance New Approach Methodologies in Translational Drug Discovery

Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities

WEST LAFAYETTE, Ind., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization (CRO) specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, and VUGENE, a multi-omics data analysis company providing advanced artificial intelligence (AI) and machine learning (ML) solutions for biomedical research, today announced a strategic collaboration designed to accelerate AI-assisted drug discovery and enhance data-driven insights across the drug development continuum.

Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities

Inotiv, Inc. (NOTV) Q4 2025 Earnings Call Transcript

Inotiv, Inc. (NOTV) Q4 2025 Earnings Call Transcript

Inotiv, Inc. (NOTV) Q4 2025 Earnings Call Transcript

Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update

– Fourth quarter fiscal 2025 revenue up 5.9% to $138.1 million– Fiscal 2025 revenue increased 4.5% to $513.0 million– Fourth quarter fiscal 2025 operating loss decreased 48.5% to $6.8 million– Fiscal 2025 operating loss decreased 64.2% to $30.9 million– Conference call scheduled for today at 4:30 pm ET

Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update

Inotiv Ranked Number 182nd Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500™

Building a Unified, Client-Focused, Early Stage CRO Through Strategic Expansion and Service Development Powers 448% Revenue Growth from Fiscal Year 2021 to Fiscal Year 2024 Building a Unified, Client-Focused, Early Stage CRO Through Strategic Expansion and Service Development Powers 448% Revenue Growth from Fiscal Year 2021 to Fiscal Year 2024

Inotiv Ranked Number 182nd Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500™

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.